A senior source close to the matter has stated that there are no ongoing discussions between AstraZeneca and Bristol Myers Squibb regarding a potential deal, quashing earlier reports of preliminary merger talks. AstraZeneca shares slid approximately 9% following the initial speculation.
The definitive denial of merger talks between AstraZeneca and Bristol Myers Squibb clarifies market speculation and highlights the sensitivity of large pharmaceutical companies to M&A rumors, impacting their stock valuations.
A senior source has definitively stated that there are no ongoing discussions between AstraZeneca and Bristol Myers Squibb regarding a potential merger, effectively quashing earlier speculation. The denial comes after Reuters reported, citing a person familiar with the situation, that the two pharmaceutical giants had held preliminary talks about a deal that could have created a company valued at nearly $400 billion. The Financial Times had initially broken the news of these potential discussions.
Following the initial reports of merger talks, AstraZeneca's shares experienced a significant decline, sliding approximately 9%. In contrast, Bristol Myers Squibb's shares remained more stable, indicating a mixed market reaction to the speculative deal.
The source emphasized that "There is no deal between AstraZeneca and BMS. There never was a deal to be done, and there are no discussions between the companies."